BioMarin Pharmaceutical (BMRN) - רווח נקי למניה (EPS TTM)

BioMarin Pharmaceutical is a leader in the therapy of rare genetic pathologies, possessing exceptional pricing power over unique medications. This 12-month EPS chart demonstrates the operational resilience of the business, where the value of -0.10 characterizes this level. Despite risks stemming from the development of gene editing, BioMarin Pharmaceutical is restructuring its portfolio, focusing on the commercial scaling of its most successful orphan drugs.

To minimize risks, investors should select assets with stable net profit dynamics, calculated as the ratio of total income to the number of shares over a rolling year. In the case of BioMarin Pharmaceutical (BMRN), this metric reflects the efficiency of monetizing joint genetic developments; therefore, sharp fluctuations in the per-share profit trend over the last 12 months may signal a revaluation of the business value.